VITA 34 International AG / Regulatory Approval/Alliance
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Leipzig, August 11, 2008 - VITA 34 International AG (ISIN DE000A0BL849), the parent company of the leading private umbilical cord blood bank in the German-speaking countries VITA 34, received IND approval of its autologous Cord Blood for a clinical study in children with Type 1 Diabetes. The study will be performed by the Diabetes Research Institute of the Klinik und Poliklinik für Kinder- und Jugendmedizin of the Technical University Munich. A corresponding approval was granted by The Paul-Ehrlich-Institute, a high federal agency in Germany. The aim of the study is to investigate the safety and potential benefit of transfusing autologous Cord Blood in children who have newly manifested Type 1 Diabetes. The study is designed to last 24 months and will be controlled by a reference group. The risk of Type 1 Diabetes in Germany is about 1 in 600 by the age of fourteen. A similar pilot study in the USA shows promising results with regard to the disturbed immune balance, insulin requirements, and the quality of metabolic control.

Press / Investor Relation: 
Axel Mühlhaus / Dr. Sönke Knop 
edicto GmbH 
Zeißelstraße 19 
D-60318 Frankfurt 
Phone: +49 (069) 90550550 
Fax  : +49 (069) 90550577 
eMail: vita34@edicto.de


11.08.2008  Financial News transmitted by DGAP

---

 
Language:     English
Issuer:       VITA 34 International AG
              Deutscher Platz 5a
              04103 Leipzig
              Deutschland
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
E-mail:       info@vita34.de
Internet:     www.vita34.de
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart  
End of News DGAP News-Service  

---